Volume 5.32 | Aug 29

Prostate Cell News 5.32 August 29, 2014
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
Symmetrical and Asymmetrical Division Analysis Provides Evidence for a Hierarchy of Prostate Epithelial Cell Lineages
Using basal and luminal cell-specific markers and cell lineage tracing transgenic mice, scientists report that in developing prostatic epithelia, basal and luminal cells exhibit distinct division modes. [Nat Commun] Abstract
ten Now: Podcast on ALDH in Breast Cancer Treatment Response
PUBLICATIONS (Ranked by impact factor of the journal)

Hexokinase 2-Mediated Warburg Effect Is Required for PTEN and p53-Deficiency-Driven Prostate Cancer Growth
Building upon insights gained from their studies with Pten/p53-deficient mouse embryonic fibroblasts, scientists report that hexokinase 2 is selectively upregulated by the combined loss of Pten and p53 in prostate cancer cells. [Cell Rep] Full Article | Graphical Abstract

Luminal Cells Are Favored as the Cell of Origin for Prostate Cancer
Scientists used a novel lineage-tracing strategy to assess the cell of origin in a diverse range of mouse models as well as a hormonal carcinogenesis model. Their results show that luminal cells are consistently the observed cell of origin for each model in situ; however, explanted basal cells from these mice can generate tumors in grafts. [Cell Rep] Full Article | Graphical Abstract

Prostate Cancer Cells Home to Bone Using a Novel In Vivo Model: Modulation by the Integrin Antagonist GLPG0187
Micrometastasis is a barrier to the development of effective cancer therapies for prostate cancer metastasis to bone. Scientists aimed to establish a new model, allowing the tracking of prostate cancer cells homing to bone, and further, to evaluate the response of this approach to therapeutic modulation, using the integrin antagonist GLPG0187. [Int J Cancer] Abstract

miR-130b Suppresses Prostate Cancer Metastasis through Down-Regulation of MMP2
Researchers found that the expression of miR-130b was significantly down-regulated in prostate cancer cell lines and clinical prostate cancer tissues. Enforced over-expression of miR-130b in prostate cancer cells suppressed whereas knock-down of miR-130b increased cell migration and invasion. [Mol Carcinog] Abstract

Prostate Cancer Stem-Like Cells Proliferate Slowly and Resist Etoposide-Induced Cytotoxicity via Enhancing DNA Damage Response
Researchers demonstrate that DU145-derived prostate cancer stem cells (PCSCs) progress slowly with more cells accumulating in the G1 phase in comparison to DU145 non-PCSCs. [Exp Cell Res] Abstract

The Presence of Androgen Receptor Elements Regulates ZEB1 Expression in the Absence of Androgen Receptor
Scientists demonstrate that a promoter construct containing both androgen response elements activates transcription of zinc finger E-box binding homeobox 1 (ZEB1) even in the androgen receptor (AR)-null cell lines DU145 and PC3. Incubation of the AR-positive cell line, LNCaP with R1881, failed to substantially increase the expression levels of ZEB1. [J Cell Biochem] Abstract

Echinophora platyloba DC (Apiaceae) Crude Extract Induces Apoptosis in Human Prostate Adenocarcinoma Cells (PC 3)
Scientists report the cytotoxicity and the mechanism of cell death of the methanolic extract prepared from E. platyloba plant against human prostate adenocarcinoma PC 3 cell line and human umbilical vein endothelial cells HUVEC cell line. [Biomed J] Abstract


Active Monitoring, Radical Prostatectomy, or Radiotherapy for Localized Prostate Cancer: Study Design and Diagnostic and Baseline Results of the ProtecT Randomized Phase III Trial
Researchers report the study design, participant sociodemographic and clinical characteristics, and the initial results of the testing and diagnostic phase of the Prostate testing for cancer and Treatment (ProtecT) trial, which aims to investigate the effectiveness of treatments for localized prostate cancer. [Lancet Oncol] Full Article

Randomized Phase II Study of Bone-Targeted Therapy Containing Strontium-89 in Advanced Castrate-Sensitive Prostate Cancer
Scientists showed that bone-targeted therapy using 1 dose of strontium-89 combined with chemohormonal ablation therapy did not favorably affect the progression-free survival of patients with castrate-sensitive prostate cancer. [Cancer] Abstract

Serum Tri- and Tetra-Antennary N-Glycan Is a Potential Predictive Biomarker for Castration-Resistant Prostate Cancer
A predictive biomarker for castration-resistant prostate cancer (CRPC) would provide useful information to physicians. Researchers evaluated the diagnostic potential of serum N-glycan profiling in CRPC. [Prostate] Abstract

ProstaCultâ„¢: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays - FREE Sample Request
SLCO and ABC Transporters: A Role for Steroid Transport in Prostate Cancer Progression
The authors discuss the emerging evidence that suggests a role for specific transporters in mediating transport of steroids into or out of prostate cells, thereby influencing intratumoral androgen levels and prostate cancer development and progression. [Endocrinology] Abstract

Pomegranate and Its Components as Alternative Treatment for Prostate Cancer
The authors discuss data on the effects of pomegranate juice and pomegranate extracts on prostate cancer. They also discuss the effects of specific components of the pomegranate fruit and how they have been used to study the mechanisms involved in prostate cancer progression and their potential to be used in deterring prostate cancer metastasis. [Int J Mol Sci] Abstract | Download Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer
Advaxis, Inc. has entered into a clinical trial collaboration agreement with Merck through its subsidiaries to evaluate the combination of Advaxis’s Lm-LLO cancer immunotherapy, ADXS-PSA, with Merck’s investigational anti PD-1 antibody, pembrolizumab. [Advaxis, Inc.] Press Release

MVI Vaccine to be Used in Clinical Trial of a New Combination Approach to Immunotherapy Funded by The Prostate Cancer Foundation and The Movember Foundation
Madison Vaccines Incorporated (MVI) announced that its lead product candidate MVI-816 will be used in a clinical trial testing a two-pronged immunotherapy approach to treat metastatic prostate cancer. [Madison Vaccines, Inc.] Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW BIT’s 8th Annual World Cancer Congress (WCC-2015)
May 15-17, 2015
Beijing, China

Visit our events page to see a complete list of events in the prostate cell community.
NEW Postdoctoral Fellowship Position – Cancer Immunology (Cornell University)

Bioinformatics Analyst / Computational Biologist – Molecular Analysis of Prostate Cancer (Cornell University)

Postdoctoral Fellow – Prostate Cancer (Cleveland Clinic)

Postdoctoral Position – Molecular Physiology in Prostate Cancer (Duke Molecular Physiology Institute)

Postdoctoral Fellow – Cancer and miR Biology (Thomas Jefferson University Hospital)

PhD Position – Prostate Cancer Research (Institute of Oncology Research)

Postdoctoral Position – Cancer Biology/Genomics (Cornell University)

Postdoctoral Research Fellow – Mechanism of Gene Regulation in Prostate Cancer Development and Bone Metastasis (Brigham & Women’s Hospital – Harvard Medical School)

Postdoctoral Fellow – Prostate Cancer Research (Institute of Oncology Research)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us